Erectile dysfunction therapy according to the European Association of Urology Guidelines

Czech version

Authors: T. Šrámková
Authors‘ workplace: Urologická klinika a Sexuologický ústav 1. LF UK a VFN v PrazeSexuologické oddělení LF MU a FN Brno
Published in: Kardiol Rev Int Med 2014, 16(4): 288-293
Category: Cardiology Review

Overview

The ideal treatment of ED considering the patient's welfare should be easy to administer, non‑invasive, painless and highly effective, with minimal side effects. Modern, oral first‑line erectile dysfunction therapy using phosphodiesterase 5 inhibitors is safe, effective and well tolerated. Intracavernosal therapy as the second‑line therapy is safe and effective in diabetic patients, in men with cardiovascular disease and in men who have undergone radical prostatectomy. A new method of erectile dysfunction therapy is low‑ intensity extracorporeal shock wave therapy which produces neovascularization. Lifestyle changes (intensive exercise and decrease in Body Mass Index) can improve erectile function.

Keywords:
erectile dysfunction – treatment – phosphodiesterase 5 inhibitors – intracavernosal therapy – shock wave therapy

Sources

1. Breza J. Erektilné poruchy. 1st ed. Martin: Osveta 1994.

2. Morus RL. Světové dějiny sexuality. Praha: Naše vojsko 1992 .

3. Scott FB, Bradley WE, Timm GW. Management of erectile impotence use of implantable inflatable prosthesis. Urology 1973; 2: 80– 82.

4. Katzenstein L. Viagra: The remarkable story of the discovery and launch. NY: Medical Information Press 2001.

5. Jackson G, Sharlip ID. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks. J Sex Med 2014; 11 (Suppl 2): S131– S132.

6. Goldstein I. Internet‑ ordered Viagra (Sildenafil Citrate) is rarely genuine. J Sex Med 2014; 11 (Suppl 2):S133– S135.

7. Hatzimouratidis K, Eardley I, Giuliano F et al. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. EAU 2014. [online] Available from: http:/ / www.uroweb.org/ gls/ pdf/ 14_Male%20Sexual%20Dysfunction_ LR.pdf.

8. European Medicines Agency. Viagra (sildenafil): EU summary of product characteristics. [online] Available from: http:/ / www.ema.europa.eu/ docs/ cs_CZ/ document_library/ EPAR__Product_Information/ human/ 000202/ WC500049830.pdf.

9. European Medicines Agency. Cialis (tadalafil): EU summary of product characteristics. [online] Available from: http:/ / www.ema.europa.eu/ docs/ cs_CZ/ document_library/ EPAR__Product_Information/ human/ 000436/ WC500026318.pdf.

10. European Medicines Agency. Levitra (vardenafil): EU summary of product characteristics. [online] Available from: http:/ / www. ema.europa.eu/ docs/ cs_CZ/ document_library/ EPAR_– _Product_Information/ human/ 000475/ WC500039992.pdf.

11. European Medicines Agency. Spedra (avanafil): EU summary of product characteristics. [online] Available from: http:/ / www.ema.europa.eu/ docs/ cs_CZ/ document_library/ EPAR__Product_Information/ human/ 002581/ WC500145206.pdf.

12. Šrámková T. Poruchy sexuality u somatických onemocnění a jejich léčba. 1st ed. Praha: Grada Publishing 2013.

13. Goldstein I, Lue TF, Padma‑ Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397– 1404.

14. Hatzichristou D, Gambla M, Rubio‑ Aurioles E et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008; 25: 138– 146. doi: 10.1111/ j.1464‑ 5491.2007.02338.x.

15. Oelke M, Giuliano F, Mirone V et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international randomised, parallel, placebo‑ controlled clinical trials. Euro Urol 2012; 61: 917– 925. doi: 10.1016/ j.eururo.2012.01.013.

16. Goldstein I, McCullough A, Jones LA et al. A randomized, double‑blind, placebo‑ controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9: 1122– 1133. doi: 10.1111/ j.1743‑ 6109.2011.02629.x.

17. Goldstein I, Jones LA, Belkoff LH et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomied, double‑blind study in men with diabetes mellitus. Mayo Clin Proc 2012; 87: 843– 852. doi: 10.1016/ j.mayocp.2012.06.016.

18. Mulhall JP, Moul JW, Wang R et al. A phase III, placebo‑controlled study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral nerve‑ sparing radical prostatectomy. J Sex Med 2012; 9: S42– S43.

19. Rosen RC, Riley A, Wagner G et al. The International Index of Eectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822– 830.

20. Gruenvald I, Kitrey ND, Appel B et al. Low‑ intensity extracorporeal shock wave therapy in vascular disease and erectile dysfunction: theory and outcomes. Sex Med Rev 2013; 1: 83– 90. doi: 10.1002/ smrj.9.

21. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873– 877.

22. Heaton JP, Lording D, Liu SN et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001; 13: 317– 321.

23. Pacík D. Chirurgické řešení erektilní dysfunkce implantací penilní protézy. Andrologie 2003; 4: 25– 30.

24. Trost L, Hellstrom WJG. History, contemporary outcomes, and future of penile prostheses: A review of the literature. Sex Med Rev 2013; 1: 150– 163. doi: 10.1002/ smrj.8.

25. Martin SA, Atlantis E, Lange K et al. Predictors of sexual dysfunction incidence and remission in men. J Sex Med 2014; 11: 1136– 1147. doi: 10.1111/ jsm.12483.

26. Gratzke C, Angulo J, Chitaley K et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 2010; 7: 445– 475. doi: 10.1111/ j.1743‑6109.2009.01624.x.